Tests ST-02 gemcitabine placed in the kidney for upper urinary tract cancer
Tests ST-02 liquid in adults with low-grade kidney urothelial cancer.
Plain-language title generated from the registry record
Registry title: Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
Key facts
- Where
- Halifax, London, Montreal, Sherbrooke, Toronto, Vancouver, and Winnipeg, CanadaSee the 8 sites
- Phase
- Phase 2/3
Where in Canada
- Centre of Applied Urology Research/Nova Scotia Health AuthorityHalifax, CanadaTaking people
- London Health Sciences Centre · Victoria HospitalLondon, CanadaTaking people
- Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, CanadaNot yet recruiting
- McGill University Health CenterMontreal, CanadaTaking people
- Centre de recherche du CHUSSherbrooke, CanadaNot yet recruiting
- UHN Princess Margaret Cancer CentreToronto, CanadaTaking people
- Vancouver Prostate CentreVancouver, CanadaTaking people
- Men's Health ClinicWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peter Black
- Trial code
- NCT06124976
- Record updated
- 3 August 2026
- Original description
The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants who have a low-grade tumor.Read full original descriptionShow less
A Phase 2/3 Multicenter Trial Evaluating the Safety and Efficacy of ST-02 (Mucoadhesive Gemcitabine Suspension) on Ablation of Urothelial Carcinomas in the Upper Urinary Tract
The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants who have a low-grade tumor.
The main questions this study aims to answer are:
1. Can ST-02 effectively eradicate UTUC by 3 months? 2. Is ST-02 safe for patients with UTUC?
Participants in this study will receive ST-02, a new formulation with gemcitabine once weekly for six weeks. Gemcitabine is known to be an effective drug in treating urothelial carcinoma. This new formulation will be instilled directly into the upper urinary tract (renal pelvis) and will allow the chemotherapeutic to work locally for an extended period of time. The administration process will be retrograde (via a small catheter inserted up into the kidney, under anesthesia) or antegrade (via a nephrostomy, in the clinic) once weekly for six weeks. Safety and efficacy will be monitored for up to a year after the initial response assessment.
Inclusion: Adult (≥ 18 years) male or female; Primary or recurrent low-grade (LG), noninvasive (Ta) Upper Tract Urothelial Carcinoma (UTUC) in the renal pelvis, infundibulum, and/or calyces, based on ureteroscopy, biopsy and cytology (disease assessment URS) performed within 8 weeks prior to or during the Screening Visit; At least 1 measurable papillary tumor measuring 5-15 mm; Low grade tumor(s) in the ipsilateral ureter. Every attempt should be made to ablate this tumor completely, but residual ipsilateral ureteral tumor is not an exclusion criterion; Prior fully ablated low grade bladder tumor(s), without the need for intravesical therapy except for single-dose chemotherapy; A life expectancy of greater than 12 months; No active untreated urinary tract infection (UTI) as confirmed by urine culture or urinalysis; Women of Child bearing potential (WoCBP) and Males who have a WoCBP partner require a negative pregnancy test at the Screening visit and must use two acceptable contraceptives methods until six months post-treatment; All sexually active males must agree to use a condom during intercourse, for at least 48 h after each instillation; eGFR ≥10 mL/min; weekly creatinine monitoring recommended during treatment for participants with eGFR <30 mL/min or a solitary functional kidney.
Exclusion: Have received Bacillus Calmette - Guerin (BCG) treatment for UTUC within 6 weeks prior to Visit 1 (D1); Unresolved infection requiring active treatment with systemic antimicrobial drugs; Actively being treated or intend to be treated with intravesical or systemic chemotherapy during the duration of the trial; Currently receiving another investigational agent or involved in a clinical trial with an investigational product within the past 30 days prior to Visit 1 (D1); History of high-grade non-muscle invasive bladder cancer within the past 6 months; History of muscle-invasive bladder cancer during the past 2 years; Active hepatitis B (chronic or acute) or active hepatitis C infection; Pregnant (positive urine pregnancy test), planning pregnancy during trial, breast-feeding, or of childbearing potential without reliable contraception; Urinary obstruction in the ipsilateral Upper Urinary Tract (UUT); Any contraindicated to gemcitabine or sensitivity to gemcitabine or any of the ST-02 ingredients.